IRCT201610098983N2已完成2 期
Evaluation of therapeutic effect intravitreal injection of methotrexate in persistent diabetic macular edema
Guilan University of Medical Sciences,Vice chancellor for research0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •1. Patient with central subfleid thickness (CST) More than 250 micrometers.
- •2. Best corrected visual acuity 20/ 200 and more.
- •3.lack of one line improvement, at least, in best corrected visual acuity or at least 10% reduction in central subfield thickness after intravitreal injection of three consecutive Bevacizumab and one injection co-administration bevacizumab -triamcinolone every 4-6week intervalor 3 consecutive Bevacizumab every 4 -6 weeks plus macular photouagulation.
- •4. Lack of traction on the macula, which is identified on clinical examination and OCT
- •5. Patient who agree entering the study (consent form)
- •Exclusion criteria :
- •1. Any previous intraocular surgery that was done in more than 1year ago
- •2. Any laser photocuagulation treatment in the past 4 months .
- •3. Need to any intraocular surgery, intraocular injection or laser photocoagulation in the follow-up period .
- •4. Any traction on the macula which is identified on clinical examination and OCT.
- •5. No control of blood pressure, blood sugar and blood lipid during study
排除标准
- 未提供
研究者
相似试验
招募中
3 期
The Comparison of Efficacy Between Iranian Made Ranibizumab and Imported Ranibizumab in Diabetic Patients with Macular EdemaIRCT20170303032845N1Aracell zist daru154
已完成
3 期
The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edemadiabetic macular edemaJPRN-UMIN000017037Jichi Medica University, Saitama Medical Center100
进行中（未招募）
不适用
Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma - NDMacular oedemaMedDRA version: 6.1Level: HLGTClassification code 10047060EUCTR2006-002351-33-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
进行中（未招募）
不适用
Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSAEUCTR2006-003170-99-ITIVERSITA DEGLI STUDI DI UDINE
招募中
1 期
Comparison of the effect of intravitreal injection of bevacizumab (Stevenet) alone with intravitreal injection of bevacizumab and triamcinolone in the treatment of diabetic macular edema with a thickness greater than 500 microns in patientsIRCT20211130053229N1Kerman University of Medical Sciences70